PharmAthene, Inc. Q2 2010 Earnings Conference Call Transcript - Thomson StreetEvents

PharmAthene, Inc. Q2 2010 Earnings Conference Call Transcript

PharmAthene, Inc. Q2 2010 Earnings Conference Call Transcript - Thomson StreetEvents
PharmAthene, Inc. Q2 2010 Earnings Conference Call Transcript
Published Aug 12, 2010
10 pages (5161 words) — Published Aug 12, 2010
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ALT.OQ earnings conference call or presentation 12-Aug-10 8:30pm GMT

  
Brief Excerpt:

...Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 PharmAthene, Incorporated Earnings Conference Call. My name is Elisha, and I'll be your coordinator for today. At this time, all participants are in listen only mode. We will be conducting a question and answer session towards the end of this conference. (Operator Instructions) I would now like to turn the presentation over to your host for today's call, Stacey Jurchison. Please proceed. Stacey Jurchison ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Altimmune Inc
Ticker
ALT.OQ
Time
8:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Steve Brozak - WBB - Analyst : Hey, congratulations, gents, on the contract award and the good news around that. I'll cut away from a different part, the part that you just mentioned. From people that were at the court hearing, there was a perception that basically there was a question as far as, well, what exactly would damages be and how would you basically assess them. And now we're looking at a situation where we're in a horizon of potential contracts being awarded. Can you give us some insight as to what that would mean?

Question: Steve Brozak - WBB - Analyst : Okay. I'll jump back in the queue. But congratulations again on the quarter and obviously on the news that you've gotten an award. And we look forward to finding out what happens this quarter. Thank you, again, gentlemen. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Nathan Cali - Noble Financial - Analyst : Hi, guys. Good afternoon. Thanks for taking the questions. Just had a couple of questions. What is being done to prepare for the trial in January? And as far as your billed and unbilled receivables, have you guys seen any progress there? I know you discussed it a little bit. Could you just go into a little bit of detail there?

Question: Nathan Cali - Noble Financial - Analyst : Okay.

Question: Nathan Cali - Noble Financial - Analyst : Okay.

Question: Nathan Cali - Noble Financial - Analyst : Okay, thanks.

Question: Matt Duffy - Black Diamond esearch - Analyst : Hey, good afternoon and thanks for taking the questions. A couple of things. One, you've got the award, and congratulations on that. But how far does the $78 million take SparVax development? Does it -- what specific trials and how far in the development process will that get you?

Question: Matt Duffy - Black Diamond esearch - Analyst : Okay, very good. And on the Protexia side, as they're making the decision here, can you give us some color on some of the decision points and what the issues are that they're weighing in terms of as they determine whether or not to go ahead with additional Protexia funding?

Question: Matt Duffy - Black Diamond esearch - Analyst : Okay, very good. Good luck with that.

Question: Matt Duffy - Black Diamond esearch - Analyst : Okay, very good.

Question: Debra Fiakas - Crystal Equity Research - Analyst : Thank you. I was wondering if you could tell us a little bit more about the manufacturing facilities for SparVax and if there is a requirement for some additional investment over the next, say, 12 months to 18 months.

Question: Debra Fiakas - Crystal Equity Research - Analyst : Excellent. And this, I think, is probably a question for Charlie. Could you please, if you would, repeat the cash figure that you provided?

Question: Debra Fiakas - Crystal Equity Research - Analyst : Okay, excellent. And then also could you tell us what the cash usage was during the second quarter, just during the June three month quarter?

Question: Debra Fiakas - Crystal Equity Research - Analyst : Excellent. Thank you.

Table Of Contents

Altimmune Inc Annual Shareholders Meeting Transcript – 2020-09-24 – US$ 54.00 – Edited Transcript of ALT.OQ shareholder or annual meeting 24-Sep-20 2:00pm GMT

Altimmune Inc Q2 2020 Earnings Call Transcript – 2020-08-12 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 12-Aug-20 12:30pm GMT

PharmAthene, Inc. Conference Call to Discuss Delaware Court of Chancery Decision Transcript – 2011-09-23 – US$ 54.00 – Edited Transcript of ALT.OQ conference call or presentation 23-Sep-11 1:00pm GMT

Pharmathene Inc Q4 2010 Earnings Conference Call Transcript – 2011-03-28 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 28-Mar-11 8:30pm GMT

PharmAthene, Inc. Q3 2010 Earnings Conference Call Transcript – 2010-11-11 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 11-Nov-10 9:30pm GMT

Pharmathene Q1 2010 Earnings Conference Call Transcript – 2010-05-11 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 11-May-10 8:30pm GMT

Pharmathene Q4 2009 Earnings Conference Call Transcript – 2010-03-23 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 23-Mar-10 8:30pm GMT

Pharmathene Conference Call to provide an update on its rPA program Transcript – 2009-12-09 – US$ 54.00 – Edited Transcript of ALT.OQ conference call or presentation 9-Dec-09 2:00pm GMT

Pharmathene Q3 2009 Earnings Conference Call Transcript – 2009-11-12 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 12-Nov-09 4:00pm GMT

Pharmathene at Maxim Group Conference Transcript – 2009-09-29 – US$ 54.00 – Edited Transcript of ALT.OQ presentation 29-Sep-09 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "PharmAthene, Inc. Q2 2010 Earnings Conference Call Transcript" Aug 12, 2010. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2010-PharmAthene-Inc-Earnings-Conference-Call-T3231178>
  
APA:
Thomson StreetEvents. (2010). PharmAthene, Inc. Q2 2010 Earnings Conference Call Transcript Aug 12, 2010. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2010-PharmAthene-Inc-Earnings-Conference-Call-T3231178>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.